Recent Advances in Precision Radiotherapy of Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2263
Special Issue Editor
Interests: precision radiotherapy; molecular radiobiology; radiation induced carcinogens; radiogenomics; radiation induced genome instability
Special Issue Information
Dear Colleagues,
The trend of cancer incidence is increasing worldwide. About 80% of cancer patients receive radiotherapy (RT) for their treatment externally or internally. However, in spite of years and years of hard work among scientists, there are still many unsolved questions in the field of radiation therapy. It took about 50 years for us to be able to use high-energy photons generated from Cobalt-60 or linear accelerators for treatment of deep-seated tumors. There has been a significant technical advancement during the last two decades in external radiation dose delivery such as intensity modulated radiotherapy (IMRT), intraoperative RT (IORT), image-guided RT (IGRT), stereotactic body RT (SBRT), and different fractionation schemes, such as hyper- and hypo-fractionation, to spare normal tissues as much as possible and achieve better radiotherapy outcomes. The introduction of three‐ and four-dimensional conformal radiation therapy (3D or 4D-CRT) has been a major advancement in radiotherapy, and it is now possible to plan and prescribe radiation doses with desired dose distribution to the entire tumor using computer-aided techniques. New radiation treatment modalities such as neutrons and proton and ion therapy continue to represent a major challenge in the management of localized human cancer. Therefore, we are still far from achieving a personalized cancer radiotherapy.
Diagnostics has decided to publish a Special Issue with the aim to collect a series of research articles and reviews from a diverse group in the scientific community to share their research regarding radiotherapy in cancer. Therefore, I cordially invite you to take part in this Special Issue with a scientific contribution.
Prof. Dr. Hossein Mozdarani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
